- ISIN
- US83086J2006
- CUSIP
- 83086J101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 2, 2015
Highlights
- Market Cap
- $28.13M
- Enterprise Value
- $20.10M
- EPS (TTM)
- -$1.45
- Gross Profit (TTM)
- -$180.01K
- EBITDA (TTM)
- $10.92M
- Year Range
- $0.57 - $5.75
- Target Price
- $12.00
- ROA (TTM)
- -295.27%
- ROE (TTM)
- -636.18%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
SKYE Performance Chart
Skye Bioscience, Inc (SKYE) is down 5.5% since the beginning of the year. At $1 per share, SKYE is trading 87.7% below its 52-week high of $6. Investors who bought $1,000 worth of SKYE shares 5 years ago would now be looking at an investment worth $18.
Loading charts...
Returns By Period
Skye Bioscience, Inc (SKYE) has returned -5.46% so far this year and -67.19% over the past 12 months. Over the last ten years, SKYE has returned -41.41% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Skye Bioscience, Inc
- 1D
- 0.21%
- 1M
- -14.53%
- YTD
- -5.46%
- 6M
- -22.96%
- 1Y
- -67.19%
- 3Y*
- -50.23%
- 5Y*
- -55.39%
- 10Y*
- -41.41%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
SKYE Monthly Returns History
Based on dividend-adjusted daily data since Apr 2, 2015, SKYE's average daily return is +0.09%, while the average monthly return is +0.21%. At this rate, an investment would double in approximately 27.5 years.
Historically, 38% of months were positive and 62% were negative. The best month was Feb 2024 with a return of +264.0%, while the worst month was Jul 2020 at -67.7%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.
On a daily basis, SKYE closed higher 41% of trading days. The best single day was Feb 27, 2024 with a return of +76.9%, while the worst single day was Oct 6, 2025 at -60.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 34.72% | -26.25% | -17.49% | 42.99% | -11.77% | -8.59% | -5.46% | ||||||
| 2025 | 13.43% | -11.21% | -44.21% | 37.11% | -9.17% | 111.11% | -14.59% | -1.96% | 12.29% | -60.56% | -15.48% | -42.77% | -73.51% |
| 2024 | 47.06% | 264.00% | 7.42% | -17.33% | -10.21% | -31.01% | -35.46% | 19.73% | -36.83% | 34.02% | -14.31% | -36.97% | 4.04% |
| 2023 | 106.79% | -8.06% | -43.51% | -23.56% | 12.78% | 42.00% | 7.98% | -21.74% | -9.11% | -57.21% | -8.00% | 68.94% | -32.84% |
| 2022 | -5.77% | -21.43% | -1.56% | -0.53% | 0.27% | -6.61% | 5.38% | -24.73% | -7.14% | -7.69% | -26.04% | -8.73% | -68.85% |
| 2021 | 87.50% | 54.67% | 2.59% | 1.47% | 14.12% | 16.76% | -3.73% | -9.68% | -25.30% | -31.20% | 9.87% | -34.18% | 30.00% |
Benchmark Metrics
Skye Bioscience, Inc has an annualized alpha of 15.81%, beta of 0.65, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since April 02, 2015.
- This stock participated in 213.38% of S&P 500 Index downside but only -42.20% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.65 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 15.81%
- Beta
- 0.65
- R²
- 0.01
- Upside Capture
- -42.20%
- Downside Capture
- 213.38%
Return for Risk
Risk / Return Rank
SKYE ranks 19 for risk / return — in the bottom 19% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Skye Bioscience, Inc (SKYE) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SKYE | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.62 | ||
| Sortino ratioReturn per unit of downside risk | -3.16 | ||
| Omega ratioGain probability vs. loss probability | 0.94 | 1.37 | -0.42 |
| Calmar ratioReturn relative to maximum drawdown | -0.77 | 2.78 | -3.55 |
| Martin ratioReturn relative to average drawdown | -0.99 | 12.44 | -13.43 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Skye Bioscience, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Skye Bioscience, Inc was 99.96%, occurring on Mar 27, 2026. The portfolio has not yet recovered.
The current Skye Bioscience, Inc drawdown is 99.95%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.96%Mar 2026 | 10y 11mo | — | 11y 2moApr 2015 - now |
Drawdown Indicators
| SKYE | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.96% | -56.78% | -43.18% |
Max Drawdown (1Y)Largest decline over 1 year | -87.85% | -9.10% | -78.75% |
Max Drawdown (3Y)Largest decline over 3 years | -96.79% | -18.90% | -77.89% |
Max Drawdown (5Y)Largest decline over 5 years | -98.66% | -25.43% | -73.23% |
Max Drawdown (10Y)Largest decline over 10 years | -99.83% | -33.92% | -65.91% |
Current DrawdownCurrent decline from peak | -99.95% | -1.80% | -98.15% |
Average DrawdownAverage peak-to-trough decline | -94.93% | -10.71% | -84.22% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 67.63% | 2.03% | +65.60% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Skye Bioscience, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Skye Bioscience, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SKYE in comparison with other companies in the Biotechnology industry. Currently, SKYE has a P/B value of 3.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with SKYE
Add Skye Bioscience, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with SKYE